
Extracef125 mg/5 m
Aristopharma Ltd.
Respiratory Tract Infections Cephradine is an established treatment for susceptible upper and lower respiratory tract infections, including pharyngitis, tonsillitis, otitis media and more.
Cephradine is an established treatment for susceptible upper and lower respiratory tract infections, including pharyngitis, tonsillitis, otitis media, and lobar pneumonia caused by susceptible strains of Streptococcus pneumoniae, Streptococcus pyogenes (Group A beta-hemolytic streptococci), Staphylococcus aureus (including penicillinase-producing strains), and Haemophilus influenzae. For streptococcal pharyngitis/tonsillitis, penicillin or amoxicillin remain the guideline-preferred first-line agents; Cephradine is an alternative for patients who cannot take a penicillin for reasons other than immediate/severe (anaphylactic-type) hypersensitivity.
Cephradine is an established treatment for uncomplicated skin and soft tissue infections caused by susceptible staphylococci and streptococci.
Cephradine is an established treatment for uncomplicated and, at higher doses, complicated urinary tract infections, including cystitis and prostatitis, caused by susceptible organisms such as Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
Cephradine has guideline- and practice-supported use as a treatment option for susceptible bone and joint infections, generally as a narrower-spectrum alternative once causative organism and susceptibility are known; it is not typically first-line empiric therapy for serious bone/joint infection.
The injectable form of Cephradine is used as an adjunct, short-course perioperative antibiotic to reduce the risk of postoperative infection in contaminated or potentially contaminated surgery; it is given as prophylaxis around the time of surgery rather than as prolonged treatment, consistent with antibiotic stewardship principles.
Cephradine is not effective against methicillin-resistant staphylococci, Pseudomonas aeruginosa, most Enterococcus species, or viral, fungal, or parasitic infections, and should be reserved for infections known or strongly suspected to be caused by susceptible bacteria.
The dose, frequency, and duration of Cephradine vary by indication, patient age, weight, and kidney function, and must be individualized by a qualified healthcare professional. Antibiotic stewardship is essential: take Cephradine exactly as prescribed by your physician; do not stop, extend, skip doses, or share Cephradine with others without medical advice, even if symptoms improve before the course is finished.
| Indication | Adult Dose | Pediatric Dose (over 9 months) |
|---|---|---|
| Respiratory tract and skin/soft tissue infections | 250–500 mg every 6 hours, or 500 mg–1 g every 12 hours | 25–50 mg/kg/day in divided doses every 6–12 hours |
| Lobar pneumonia | 500 mg every 6 hours, or 1 g every 12 hours | 25–50 mg/kg/day in divided doses |
| Otitis media | Not typically an adult indication | 75–100 mg/kg/day in divided doses every 6–12 hours (not to exceed 4 g/day) |
| Uncomplicated urinary tract infection (cystitis) | 500 mg every 12 hours | 25–50 mg/kg/day in divided doses |
| Complicated urinary tract infection / prostatitis | 500 mg every 6 hours, or 1 g every 12 hours | Not established |
| Injectable (moderate to severe infections) | 2–4 g/day in divided doses (up to 8 g/day in life-threatening infection, by IM or slow IV) | 50–100 mg/kg/day in divided doses (up to 300 mg/kg/day in severe infection, under close medical supervision) |
| Perioperative surgical prophylaxis (injectable) | 1–2 g given shortly before surgery, as a short course | Not established |
For streptococcal pharyngitis/tonsillitis, treatment with Cephradine should continue for at least 10 days to reduce the risk of rheumatic fever and post-streptococcal glomerulonephritis. For most other infections, Cephradine is generally continued for at least 48–72 hours after the patient becomes asymptomatic or evidence of bacterial eradication is obtained (see Duration of Treatment). Dosing of Cephradine must be reduced in patients with renal impairment (see Use in Special Populations).
Cephradine is contraindicated in patients with known hypersensitivity to Cephradine or to any other cephalosporin-class antibiotic.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.